Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by boozehound3on Feb 08, 2019 3:26pm
73 Views
Post# 29339736

RE:RE:RE:ACST - NEWS OUT -2 dollar next week

RE:RE:RE:ACST - NEWS OUT -2 dollar next weeksorry francine            you will get no answers to critical questions        there is no plan for a deal and no plan for expanded commercialization ( if there was, we the shareholders will pay with major dilution) you and i had this discussion already they have no money for anything,  they are at the mercy of amarin. as we     get closer to the end of summer, the money will be gone and there will be another financing you watch.    they will have to drum up money for the large salaries.

they will be forced to some sort of deal witch brings in enough money to continue on to pay salaries it will do nothing for the share price

you are right the market doesn't care about any of their end points because they mean nothing until the fda accepts amarins results

the market smells blood when money is needed and punished stocks like this

the miracle already happened with the amarin results and look where we are at. there are no more miracles or surprises to come that can propell this thing.  amarin is not going to be bought out anytime soon and they are years ahead of us. they may need another trial as the medical community still doesn't beleive in the results

you will learn nothing from the call  and the shareprice will reflect that    JUST WATCH!
Bullboard Posts